The Sub-Committee on Biological Products stated that on grounds of safety, quality and efficacy it was unable to recommend that the Product Licence be varied for Travenol Laboratories Ltd Hemofil product. It considered that justification should be provided for the inclusion and choice of the heat treatment step and that there was inadequate evidence as to the safety and efficacy of the product.